TVB-2640
STU 022017-058
Phase 2 small_molecule active
Quick answer
TVB-2640 for KRAS Gene Mutation is a Phase 2 program (small_molecule) at Sagimet Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sagimet Biosciences
- Indication
- KRAS Gene Mutation
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active